FDA-APPROVED PRESCRIPTION DRUG

Botox (Botulinum Toxin)

A bacterial protein neurotoxin that's become one of the most widely used FDA-approved drugs in cosmetic and medical care. It sits at the edge of the peptide world, biologically a protein, culturally a mainstream prescription drug.

A note on scope: Botox sits at the edge of "peptide" territory

Botulinum toxin is a protein, but it's not a peptide in the way the rest of this site uses the word. It's a large bacterial neurotoxin (about 150 kilodaltons), administered only by trained clinicians, available only by prescription in regulated medical settings, and its mechanism (cleaving the SNARE protein SNAP-25 to block acetylcholine release) is fundamentally different from the receptor-agonist peptides covered elsewhere on the site. We cover it here because readers ask about it. The right home for someone really wanting to learn about Botox is a dermatology or aesthetics resource, not a peptide site.

The 30-second read

Botulinum toxin is a protein produced by the bacterium Clostridium botulinum, the same organism that causes the foodborne illness botulism. In purified, controlled medical doses, it temporarily blocks signal transmission at neuromuscular junctions, causing localized muscle relaxation that lasts roughly three to four months. Botox (onabotulinumtoxinA) was first FDA-approved in 1989 for strabismus and blepharospasm; cosmetic approval for glabellar lines came in 2002. The list of FDA-approved indications has grown substantially since, chronic migraine, overactive bladder, hyperhidrosis, cervical dystonia, spasticity, and several others. It's a prescription medical procedure performed by clinicians, not a self-injected peptide. Multiple FDA-approved brands now exist alongside the original Botox.

Why this is on people's radar

Botox is one of the most culturally familiar prescription drugs in the world. The cosmetic story most people know, temporary smoothing of dynamic facial wrinkles by relaxing the underlying muscles, is real, the FDA approved it for that use in 2002, and it's now a routine procedure performed in dermatology and aesthetic-medicine clinics globally. The cultural footprint extends well beyond cosmetics: chronic migraine sufferers, people with severe underarm sweating, patients with neurological spasticity disorders, and people with overactive bladder are all groups where Botox has FDA-approved therapeutic uses with substantial clinical evidence.

The reason Botox sometimes gets mentioned in peptide conversations is mostly biochemistry-by-association. It's a protein, like many of the compounds covered on this site. It's injected, like many of them. And there's a related family of cosmetic peptides, argireline (acetyl hexapeptide-8), syn-ake, snap-8, that are sometimes marketed as "topical Botox alternatives" because they target a similar neurotransmitter-release pathway through different mechanisms. But Botox itself is not a research peptide. It's a prescription drug, administered by licensed clinicians, with decades of clinical data behind it. Its presence on this site is more of a "people ask, so here's the explanation" page than a typical research-peptide explainer.

What people use it for (medically and cosmetically)

Botox has a wide range of FDA-approved indications:

  • Cosmetic: Smoothing dynamic facial wrinkles (glabellar / "11" lines, crow's feet, forehead lines)
  • Migraine: Reducing chronic migraine frequency in patients with 15+ headache days per month
  • Hyperhidrosis: Reducing severe underarm sweating
  • Bladder: Treating overactive bladder and urinary incontinence
  • Movement disorders: Cervical dystonia, blepharospasm, limb spasticity from stroke or cerebral palsy
  • Strabismus: Crossed eyes (the original FDA indication, 1989)
  • Off-label: Bruxism (teeth grinding), masseter slimming, gummy smile, and several other dermatology uses

What the science actually shows

Plain-English summary:

For cosmetic glabellar lines, evidence is strong and longstanding

Multiple randomized controlled trials have shown botulinum toxin produces consistent, temporary reduction in dynamic glabellar wrinkle severity. Effects typically last 3–4 months. This is the use case most people associate with Botox.1

For chronic migraine, the PREEMPT trials established efficacy

The PREEMPT-1 and PREEMPT-2 trials in 2010 led to FDA approval for chronic migraine prophylaxis. Patients with 15+ headache days per month saw consistent reduction in headache day frequency.2

For hyperhidrosis and overactive bladder, evidence is similarly solid

FDA-approved indications for both conditions are supported by randomized trial evidence showing meaningful symptom reduction lasting several months per treatment cycle.3

For movement disorders, the clinical evidence is the original use case

Cervical dystonia, blepharospasm, strabismus, and limb spasticity were the medical conditions that originally drove FDA approval. The clinical evidence for these neurological indications is decades old and well established.4

Side effects are usually mild and local, occasionally more significant

Common side effects include injection-site bruising, headache, and (uncommonly) eyelid drooping or asymmetry from medication migration. Rare serious events have been reported and are addressed in the boxed warning on FDA labels.5

The honest read

What's solid:

Botulinum toxin in the hands of trained clinicians, used at FDA-approved doses for FDA-approved indications, is one of the most well-studied injectable drugs in modern medicine. The mechanism is understood, the duration is predictable, and the safety record at approved doses is extensive.

What's still being worked out:

Several off-label cosmetic and dermatology applications (masseter slimming, gummy smile, "Baby Botox" microdosing, scalp Botox for hair-smoothing) have growing case-series literature but vary in how rigorously they've been studied. New formulations and longer-acting products continue to be evaluated.

What's hyped beyond the evidence:

"Topical Botox" claims for cosmetic peptide creams (argireline, syn-ake), these are different molecules acting through different mechanisms, with substantially less evidence than the actual injection. Some longevity-and-aesthetics framings overstate what the cosmetic effect can achieve. Botox isn't a "preventative anti-aging" treatment in any meaningful sense; it's a temporary cosmetic intervention.

Things to know if you're looking into it

  • Prescription medical procedure: Botox is administered by licensed clinicians (dermatologists, plastic surgeons, ophthalmologists, neurologists, nurse injectors under physician supervision). It's not self-administered.
  • Multiple approved brands: Onabotulinumtoxin A (Botox), abobotulinumtoxin A (Dysport), incobotulinumtoxin A (Xeomin), prabotulinumtoxin A (Jeuveau), and daxibotulinumtoxin A (Daxxify) are all FDA-approved botulinum toxin products with different formulations.
  • Effect duration: typically 3–4 months for most indications. Longer-acting products (Daxxify) have been approved with 6-month duration claims.
  • Boxed warning: the FDA label includes a boxed warning about the rare possibility of toxin spread beyond the injection site. Serious cases are rare at approved doses but have been reported.
  • Counterfeit risk: the FDA periodically warns about counterfeit Botox products. Treatment in licensed medical settings is the protective context.
  • Cost framing: typical cosmetic treatment costs $300–$700+ per area in the US, depending on geography and provider. Insurance often covers FDA-approved medical indications (migraine, spasticity, etc.) but not cosmetic use.
  • Mechanism, formulations, and references: in the "Want to go deeper?" section below.

What people often ask

Is Botox a peptide?

Technically, botulinum toxin is a large protein (~150 kDa), so by the broadest biochemical definition it's a polypeptide. Functionally and culturally, though, it's a prescription neurotoxin drug administered as a medical procedure, not a research peptide. Its inclusion on this site is mostly to answer the question "is this related to the peptides I've been hearing about?" with a clear "no, here's how it's different."

Are "peptide alternatives to Botox" real?

Cosmetic peptides like argireline (acetyl hexapeptide-8), syn-ake, and snap-8 are sometimes marketed as "topical Botox alternatives." They target the same neurotransmitter-release machinery (SNARE proteins) through different mechanisms. The honest read: as topical creams, they have far weaker evidence than injectable botulinum toxin. They aren't equivalent. They may produce some skin-feel and very modest dynamic-line effects in some users, but the comparison to Botox itself is marketing, not pharmacology.

Is it safe?

At FDA-approved doses, in the hands of trained clinicians, the safety record is extensive. The boxed-warning concern about toxin spread beyond the injection site is real but rare at approved doses. Counterfeit or unregulated products carry meaningfully higher risk and have been associated with serious adverse events.

How long does it last?

For most indications and brands, 3–4 months. Daxxify, a newer FDA-approved product with a different formulation, has approved labeling for longer duration (around 6 months for glabellar lines).

Will it make my face look "frozen"?

Outcome depends substantially on the dose, the technique, and the experience of the injector. Modern aesthetic practice tends toward smaller, more conservative dosing with the goal of softening rather than eliminating expression. Choice of clinician matters.

FDA and regulatory status

Status as of May 5, 2026: Onabotulinumtoxin A (Botox / Botox Cosmetic) is FDA-approved for an extensive list of indications including: glabellar lines (2002), forehead lines (2017), crow's feet (2013), chronic migraine (2010), cervical dystonia (2000), upper limb spasticity (2010), lower limb spasticity (2016), overactive bladder (2013), urinary incontinence due to neurologic conditions (2011), severe primary axillary hyperhidrosis (2004), strabismus and blepharospasm (1989), and several pediatric indications. Other FDA-approved botulinum toxin products include Dysport, Xeomin, Jeuveau, and Daxxify. All carry a boxed warning regarding potential distant spread of toxin effect. Status updates land here when they happen.

Want to go deeper? Mechanism, the SNARE story, formulations, and references.

Background

Botulinum toxin is produced by Clostridium botulinum, an anaerobic bacterium found in soil and improperly preserved foods. There are seven serotypes (A through G); type A is the basis of all FDA-approved cosmetic and most medical products, with type B (rimabotulinumtoxinB / Myobloc) approved for cervical dystonia. Allan Scott pioneered medical use for strabismus in the 1970s and 1980s, leading to the original 1989 FDA approval for strabismus and blepharospasm. Cosmetic glabellar approval came in 2002, and the indication list has expanded substantially since.

Mechanism of action

Botulinum toxin acts at presynaptic motor nerve terminals at the neuromuscular junction. It binds to the synaptic vesicle protein SV2, is internalized, and its light chain, a zinc-dependent protease, cleaves SNAP-25, a SNARE protein required for synaptic vesicle docking and acetylcholine release. The result is temporary inhibition of acetylcholine release at the targeted neuromuscular junctions, producing localized muscle paralysis. Effects are local because the protein doesn't migrate substantially from the injection site at typical doses. Effects are temporary because nerve terminals sprout new functional endings over weeks to months, restoring transmission.

Approved formulations

Type A (most products): onabotulinumtoxin A (Botox / Botox Cosmetic), abobotulinumtoxin A (Dysport), incobotulinumtoxin A (Xeomin), prabotulinumtoxin A (Jeuveau), daxibotulinumtoxin A (Daxxify). Different formulations have different potency, diffusion characteristics, and onset/duration profiles. Unit doses are not interchangeable between products.

Type B: rimabotulinumtoxin B (Myobloc), approved for cervical dystonia.

Approved dosing

Doses are highly indication-specific and product-specific. Cosmetic glabellar dosing for onabotulinumtoxin A is typically 20 units total across five injection sites. Therapeutic indications use substantially higher doses (e.g., 155–195 units for chronic migraine across 31–39 sites). All dosing is determined and administered by licensed clinicians in accordance with FDA-approved labeling. This site does not provide self-administration guidance.

References

  1. Carruthers JD, Carruthers JA. (1992). "Treatment of glabellar frown lines with C. botulinum-A exotoxin." J Dermatol Surg Oncol, 18(1), 17–21. PubMed
  2. Aurora SK, et al. (2010). "OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial." Cephalalgia, 30(7), 793–803. PubMed
  3. Naumann M, et al. (2008). "Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain." Neurology, 70(19), 1707–1714. PubMed
  4. Scott AB. (1980). "Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery." Ophthalmology, 87(10), 1044–1049. PubMed
  5. U.S. Food and Drug Administration. "Botox (onabotulinumtoxinA) Prescribing Information," including boxed warning. FDA.gov
  6. Pirazzini M, et al. (2017). "Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology." Pharmacol Rev, 69(2), 200–235. PubMed
For educational and research purposes only. This is not medical advice. Botulinum toxin is a prescription drug administered by licensed clinicians; this page is informational and is not intended to guide self-administration. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.